Jeffrey Libson

Jeff Libson has practiced for 35+ years and is widely regarded as one of the leading life sciences practitioners in the eastern United States. His focus is on representing life sciences companies in business matters, including governance, financings, M&A and strategic transactions. For the past 15 years Jeff has been an adjunct professor at The Wharton School of the University of Pennsylvania where he teaches a graduate business course in life sciences entrepreneurship.

Jeff represents numerous venture-backed and publicly traded life sciences companies as outside corporate counsel. He also represents a number of nonprofit entities that support and serve the life sciences community.

Jeff has deep experience with securities and venture financing matters. He has represented both issuers and underwriters in initial public offerings,follow-on offerings) and private placements of equity and debt securities and has counseled on more than 500 venture capital financings on both the company and investor side.

He has also been involved with a number of mergers and acquisition transactions. He has advised buyers, sellers and investors in numerous acquisition, disposition and combination transactions involving both public and private companies across the biotech, diagnostics, pharmaceutical, healthcare and digital health sectors, among others.

Jeff is actively engaged in the life of the community. He currently serves as a board member of the Sabin Vaccine Institute in Washington, D.C. He also serves as counsel to the national Association of Biosciences Financial Officers. In addition, he is a board member (former Board Chair) of Broad Street Ministry, a faith-based nonprofit organization that provides a variety of social services to the neediest residents of the Philadelphia community.

He has also served on the boards of Life Sciences Pennsylvania (formerly, Pennsylvania Bio), BioStrategy Partners, The Pennsylvania Life Sciences Institute and The Friends’ Central School. In addition, he has served as the co-chair of the Pennsylvania Bio – BioNJ Annual Symposium, the co-chair of the Mid-Atlantic Venture Conference and the inaugural co-chair of the Early Stage East Bio-Life-Tech venture capital conference.

Representative transactions include:

• A number of venture capital-backed biotechnology and specialty-pharma companies, as counsel, in their initial public offerings and follow-on offerings
• Venture capital-backed diagnostics company in its $850 million sale, following a strategic process whereby, with our assistance, the company was positioned to simultaneously execute an initial public offering or a private equity transaction, in addition to the ensuing M&A sale
• Leading US pediatric hospital and research institution in the organization, private financing and initial public offering of a spin-out gene therapy company, along with several subsequent monetization transactions
• Public biotechnology company in the establishment of a “universal shelf” registration statement and an $80 million underwritten “take down” public offering
• Public biotechnology company in a $150 million private placement of convertible debt under Rule 144A
• Biotechnology venture capital fund in several public offerings of “portfolio company” securities
• Several biotechnology companies in initial, follow-on and mezzanine venture capital and institutional equity financing transactions
• One of the largest US biotechnology venture capital funds and other venture capital funds (including global pharma corporate venture funds) in more than 500 financing and related transactions
• Venture capital-backed biotechnology company (vaccine development) in connection with its merger into a publicly traded biotechnology company
• Biotechnology company in connection with a multimillion-dollar private placement of its common stock
• Digital health company focused on reducing hospital readmissions and improving overall patient outcomes, in connection with its exit process and acquisition by NaviHealth, an affiliate of Cardinal Health
• International nonprofit TB vaccine development organization in the sale of its biologics manufacturing division to a German biologics contract manufacturing company